Diagnosis and treatment of chronic acquired demyelinating polyneuropathies

Nature Reviews Neurology

Volumn 10, Issue 8, 2014, Pages 435-446

  Latov, Norman ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; PLASMAPHERESIS; POLYNEUROPATHIES; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING;

EID: 84905681937     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2014.117     Document Type: Review

References (195)

1. Rajabally, Y. A., Simpson, B. S., Beri, S., Bankart, J. & Gosalakkal, J. A. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve 39, 432-438 (2009).
2. Mahdi-Rogers, M. & Hughes, R. A. Epidemiology of chronic inflammatory neuropathies in southeast England. Eur. J. Neurol. 21, 28-33 (2013).
3. Nasu, S. et al. Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy. J. Neurol. Neurosurg. Psychiatry 83, 476-479 (2012).
4. Cats, E. A. et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology 75, 818-825 (2010).
5. Nobile-Orazio, E. Multifocal motor neuropathy. J. Neuroimmunol. 115, 4-18 (2001).
6. Nobile-Orazio, E. et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann. Neurol. 36, 416-424 (1994).
7. Ellie, E. et al. Neuropathy associated with "benign" anti-myelin-associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases. J. Neurol. 243, 34-43 (1996).
8. Latov, N., Hays, A. P. & Sherman, W. H. Peripheral neuropathy and anti-MAG antibodies. Crit. Rev. Neurobiol. 3, 301-332 (1988).
9. Dispenzieri, A. POEMS syndrome: 2014 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 89, 214-223 (2014).
10. Soubrier, M. J., Dubost, J. J. & Sauvezie, B. J. POEMS syndrome: a study of 25 cases and a review of the literature. French Study Group on POEMS Syndrome. Am. J. Med. 97, 543-553 (1994).
11. McMillan, H. J., Kang, P. B., Jones, H. R. & Darras, B. T. Childhood chronic inflammatory demyelinating polyradiculoneuropathy: combined analysis of a large cohort and eleven published series. Neuromuscul. Disord. 23, 103-111 (2013).
12. Iijima, M. et al. Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J. Neurol. Neurosurg. Psychiatry 79, 1040-1043 (2008).
13. Eftimov, F., Vermeulen, M., van Doorn, P. A., Brusse, E. & van Schaik, I. N. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology 78, 1079-1084 (2012).
14. Lewis, R. A., Sumner, A. J. & Shy, M. E. Electrophysiological features of inherited demyelinating neuropathies: a reappraisal in the era of molecular diagnosis. Muscle Nerve 23, 1472-1487 (2000).
15. Sivera, R. et al. Charcot-Marie-Tooth disease: genetic and clinical spectrum in a Spanish clinical series. Neurology 81, 1617-1625 (2013).
16. Vallat, J. M. et al. Diagnostic value of nerve biopsy for atypical chronic inflammatory demyelinating polyneuropathy: evaluation of eight cases. Muscle Nerve 27, 478-485 (2003).
17. Dyck, P. J. et al. Chronic inflammatory polyradiculoneuropathy. Mayo Clin. Proc. 50, 621-637 (1975).
18. Dyck, P. J., Johnson, W. J., Lambert, E. H. & O'Brien, P. C. Segmental demyelination secondary to axonal degeneration in uremic neuropathy. Mayo Clin. Proc. 46, 400-431 (1971).
19. Buchthal, F. & Behse, F. Peroneal muscular atrophy (PMA) and related disorders. I. Clinical manifestations as related to biopsy findings, nerve conduction and electromyography. Brain 100, 41-66 (1977).
20. Cornblath, D. R. et al. Nerve conduction studies in amyotrophic lateral sclerosis. Muscle Nerve 15, 1111-1115 (1992).
21. [No authors listed] Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an ad hoc subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 41, 617-618 (1991).
22. rd. Current diagnosis of CIDP: the need for biomarkers. J. Peripher. Nerv. Syst. 16 (Suppl. 1), 3-13 (2011).
23. Bromberg, M. B. Review of the evolution of electrodiagnostic criteria for chronic inflammatory demyelinating polyradicoloneuropathy. Muscle Nerve 43, 780-794 (2011).
24. De Sousa, E. A., Chin, R. L., Sander, H. W., Latov, N. & Brannagan, T. H. 3rd. Demyelinating findings in typical and atypical chronic inflammatory demyelinating polyneuropathy: sensitivity and specificity. J. Clin. Neuromuscul. Dis. 10, 163-169 (2009).
25. Gorson, K. C. et al. Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J. Peripher. Nerv. Syst. 15, 326-333 (2010).
26. Rajabally, Y. A., Jacob, S. & Hbahbih, M. Optimizing the use of electrophysiology in the diagnosis of chronic inflammatory demyelinating polyneuropathy: a study of 20 cases. J Peripher. Nerv. Syst. 10, 282-292 (2005).
27. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision. J. Peripher. Nerv. Syst. 15, 1-9 (2010).
28. Behse, F. & Buchthal, F. Sensory action potentials and biopsy of the sural nerve in neuropathy. Brain 101, 473-493 (1978).
29. Krarup, C. & Trojaborg, W. Sensory pathophysiology in chronic acquired demyelinating neuropathy. Brain 119, 257-270 (1996).
30. Boukhris, S. et al. Atypical electrophysiologic findings in chronic inflammatory demyelinating polyneuropathy (CIDP)-diagnosis confirmed by nerve biopsy. Neurophysiol. Clin. 34, 71-79 (2004).
31. Haq, R. U. et al. Chronic inflammatory demyelinating polyradiculoneuropathy: a study of proposed electrodiagnostic and histologic criteria. Arch. Neurol. 57, 1745-1750 (2000).
32. Logigian, E. L., Kelly, J. J. Jr & Adelman, L. S. Nerve conduction and biopsy correlation in over 100 consecutive patients with suspected polyneuropathy. Muscle Nerve 17, 1010-1020 (1994).
33. Viala, K. et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy. J. Peripher. Nerv. Syst. 15, 50-56 (2010).
34. Yato, M., Ohkoshi, N., Sato, A., Shoji, S. & Kusunoki, S. Ataxic form of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Eur. J. Neurol. 7, 227-230 (2000).
35. Chin, R. L. et al. Sensory CIDP presenting as cryptogenic sensory polyneuropathy. J. Peripher. Nerv. Syst. 9, 132-137 (2004).
36. Ayrignac, X. et al. Sensory chronic inflammatory demyelinating polyneuropathy: an under-recognized entity? Muscle Nerve 48, 727-732 (2013).
37. Sinnreich, M. et al. Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia. Neurology 63, 1662-1669 (2004).
38. Dyck, P. J. et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann. Neurol. 11, 136-141 (1982).
39. Austin, J. H. Recurrent polyneuropathies and their corticosteroid treatment; with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone. Brain 81, 157-192 (1958).
40. Koller, H., Kieseier, B. C., Jander, S. & Hartung, H. P. Chronic inflammatory demyelinating polyneuropathy. N. Engl. J. Med. 352, 1343-1356 (2005).
41. Kuwabara, S., Ogawara, K., Misawa, S., Mori, M. & Hattori, T. Distribution patterns of demyelination correlate with clinical profiles in chronic inflammatory demyelinating polyneuropathy. J. Neurol. Neurosurg. Psychiatry 72, 37-42 (2002).
42. Rotta, F. T. et al. The spectrum of chronic inflammatory demyelinating polyneuropathy. J. Neurol. Sci. 173, 129-139 (2000).
43. Hattori, N. et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J. Neurol. Sci. 184, 57-63 (2001).
44. Caporale, C. M., Staedler, C., Gobbi, C., Bassetti, C. L. & Uncini, A. Chronic inflammatory lumbosacral polyradiculopathy: a regional variant of CIDP. Muscle Nerve 44, 833-837 (2011).
45. Viala, K. et al. Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain 127, 2010-2017 (2004).
46. rd. Distal acquired demyelinating symmetric polyneuropathy progressing to classic chronic inflammatory demyelinating polyneuropathy and response to fludarabine and cyclophosphamide. Muscle Nerve 47, 292-296 (2013).
47. Verma, A. et al. Focal neuropathy preceding chronic inflammatory demyelinating polyradiculoneuropathy by several years. Acta Neurol. Scand. 81, 516-521 (1990).
48. van Dijk, G. W., Notermans, N. C., Franssen, H. & Wokke, J. H. Development of weakness in patients with chronic inflammatory demyelinating polyneuropathy and only sensory symptoms at presentation: a long-term follow-up study. J. Neurol. 246, 1134-1139 (1999).
49. Bairactaris, C. et al. Early neurophysiological evolution of chronic inflammatory demyelinating polyneuropathy in a patient with Hashimoto's thyroiditis. Muscle Nerve 38, 1518-1522 (2008).
50. Adachi, Y. et al. Brachial and lumbar plexuses in chronic inflammatory demyelinating polyradiculoneuropathy: MRI assessment including apparent diffusion coefficient. Neuroradiology 53, 3-11 (2011).
51. Zaidman, C. M. & Pestronk, A. Nerve size in CIDP varies with disease activity and therapy response over time: a retrospective ultrasound study. Muscle Nerve http://dx.doi.org/10.1002/mus.24227.
52. Di Troia, A. et al. Clinical features and anti-neural reactivity in neuropathy associated with IgG monoclonal gammopathy of undetermined significance. J. Neurol. Sci. 164, 64-71 (1999).
53. Latov, N. Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann. Neurol. 37 (Suppl. 1), S32-S42 (1995).
54. rd, Magda, P. & Latov, N. Characterization of neuropathies associated with elevated IgM serum levels. J. Neurol. Sci. 228, 155-160 (2005).
55. Manji, H. Drug-induced neuropathies. Handb. Clin. Neurol. 115, 729-742 (2013).
56. Mohamed, A., Davies, L. & Pollard, J. D. Conduction block in vasculitic neuropathy. Muscle Nerve 21, 1084-1088 (1998).
57. Mathis, S., Magy, L., Diallo, L., Boukhris, S. & Vallat, J. M. Amyloid neuropathy mimicking chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 45, 26-31 (2012).
58. Latov, N. Biomarkers of CIDP in patients with diabetes or CMT1. J. Peripher. Nerv. Syst. 16, 14-17 (2011).
59. Oh, S. J. et al. Multifocal motor sensory demyelinating neuropathy: inflammatory demyelinating polyradiculoneuropathy. Neurology 65, 1639-1642 (2005).
60. Nagamatsu, M. et al. Axonal and perikaryal involvement in chronic inflammatory demyelinating polyneuropathy. J. Neurol. Neurosurg. Psychiatry 66, 727-733 (1999).
61. Bouchard, C. et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 52, 498-503 (1999).
62. Rizzuto, N. et al. Focal lesions area feature of chronic inflammatory demyelinating polyneuropathy (CIDP). Acta Neuropathol. 96, 603-609 (1998).
63. Prineas, J. W. & McLeod, J. G. Chronic relapsing polyneuritis. J. Neurol. Sci. 27, 427-458 (1976).
64. Sommer, C. et al. Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP. Neurology 65, 1924-1929 (2005).
65. Vital, C. et al. Chronic inflammatory demyelinating polyneuropathy: immunopathological and ultrastructural study of peripheral nerve biopsy in 42 cases. Ultrastruct. Pathol. 24, 363-369 (2000).
66. Latov, N. et al. Plasma-cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral-nerve myelin. N. Engl. J. Med. 303, 618-621 (1980).
67. Chassande, B. et al. Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases. Muscle Nerve 21, 55-62 (1998).
68. Pedersen, S. F., Pullman, S. L., Latov, N. & Brannagan, T. H. 3rd. Physiological tremor analysis of patients with anti-myelin-associated glycoprotein associated neuropathy and tremor. Muscle Nerve 20, 38-44 (1997).
69. Kaku, D. A., England, J. D. & Sumner, A. J. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain 117, 941-947 (1994).
70. Trojaborg, W., Hays, A. P., van den Berg, L., Younger, D. S. & Latov, N. Motor conduction parameters in neuropathies associated with anti-MAG antibodies and other types of demyelinating and axonal neuropathies. Muscle Nerve 18, 730-735 (1995).
71. Kawagashira, Y. et al. IgM MGUS anti-MAG neuropathy with predominant muscle weakness and extensive muscle atrophy. Muscle Nerve 42, 433-435 (2010).
72. Luigetti, M., Madia, F., Conte, A., Tonali, P. & Sabatelli, M. Neuropathy with predominant small fiber involvement associated with abnormal anti-MAG titer. Intern. Med. 49, 2627-2629 (2010).
73. Garces-Sanchez, M. et al. Antibodies to myelin-associated glycoprotein (anti-Mag) in IgM amyloidosis may influence expression of neuropathy in rare patients. Muscle Nerve 37, 490-495 (2008).
74. Thomas, F. P. et al. Vasculitic neuropathy in a patient with cryoglobulinemia and anti-MAG IGM monoclonal gammopathy. Muscle Nerve 15, 891-898 (1992).
75. Vital, A. et al. Anti-myelin-associated glycoprotein antibodies and endoneurial cryoglobulin deposits responsible for a severe neuropathy. Acta Neuropathol. 102, 409-412 (2001).
76. Jensen, T. S. et al. IgM monoclonal gammopathy and neuropathy in two siblings. J. Neurol. Neurosurg. Psychiatry 51, 1308-1315 (1988).
77. Manschot, S. M., Notermans, N. C., van den Berg, L. H., Verschuuren, J. J. & Lokhorst, H. M. Three families with polyneuropathy associated with monoclonal gammopathy. Arch. Neurol. 57, 740-742 (2000).
78. Piscosquito, G. et al. Coexistence of Charcot-Marie-Tooth disease type 1A and anti-MAG neuropathy. J. Peripher. Nerv. Syst. 18, 185-188 (2013).
79. Gregory, R. et al. Coexistence of hereditary motor and sensory neuropathy type Ia and IgM paraproteinemic neuropathy. Ann. Neurol. 33, 649-652 (1993).
80. Jurici, S. et al. An autopsy case of amyotrophic lateral sclerosis with Waldenström macroglobulinemia and anti-MAG gammopathy. Case Rep. Neurol. 3, 294-300 (2011).
81. Rowland, L. P. et al. Autopsy-proven amyotrophic lateral sclerosis, Waldenström's macroglobulinemia, and antibodies to sulfated glucuronic acid paragloboside. Neurology 45, 827-829 (1995).
82. Nobile-Orazio, E. et al. Neuropathy and anti-MAG antibodies without detectable serum M-protein. Neurology 34, 218-221 (1984).
83. Meucci, N. et al. Anti-myelin-associated glycoprotein antibodies predict the development of neuropathy in asymptomatic patients with IgM monoclonal gammopathy. Ann. Neurol. 46, 119-122 (1999).
84. Weiss, M. D., Dalakas, M. C., Lauter, C. J., Willison, H. J. & Quarles, R. H. Variability in the binding of anti-MAG and anti-SGPG antibodies to target antigens in demyelinating neuropathy and IgM paraproteinemia. J. Neuroimmunol. 95, 174-184 (1999).
85. Van den Berg, L. et al. Anti-MAG and anti-SGPG antibodies in neuropathy. Muscle Nerve 19, 637-643 (1996).
86. McGinnis, S., Kohriyama, T., Yu, R. K., Pesce, M. A. & Latov, N. Antibodies to sulfated glucuronic acid containing glycosphingolipids in neuropathy associated with anti-MAG antibodies and in normal subjects. J. Neuroimmunol. 17, 119-126 (1988).
87. Vital, A., Vital, C., Julien, J., Baquey, A. & Steck, A. J. Polyneuropathy associated with IgM monoclonal gammopathy. Immunological and pathological study in 31 patients. Acta Neuropathol. 79, 160-167 (1989).
88. Launay, M. et al. Anti-MAG paraproteinemic demyelinating polyneuropathy: a clinical, biological, electrophysiological and anatomopathological descriptive study of a 13-patients' cohort [French]. Rev. Neurol. (Paris) 165, 1071-1079 (2009).
89. Smith, I. S. et al. Chronic demyelinating neuropathy associated with benign IgM paraproteinaemia. Brain 106, 169-195 (1983).
90. Vrethem, M., Larsson, B., von Schenck, H. & Ernerudh, J. Immunofixation superior to plasma agarose electrophoresis in detecting small M-components in patients with polyneuropathy. J. Neurol. Sci. 120, 93-98 (1993).
91. Caudie, C. et al. Monoclonal IgM autoantibody activity vis-à-vis glycoconjugates of peripheral nerves: apropos of 112 cases [French]. Ann. Biol. Clin. (Paris) 59, 567-577 (2001).
92. Willison, H. J. et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 124, 1968-1977 (2001).
93. Noguchi, M. et al. Multifocal motor neuropathy caused by a B-cell lymphoma producing a monoclonal IgM autoantibody against peripheral nerve myelin glycolipids GM1 and GD1b. Br. J. Haematol. 123, 600-605 (2003).
94. Freddo, L. et al. Gangliosides GM1 and GD1b are antigens for IgM M-protein in a patient with motor neuron disease. Neurology 36, 454-458 (1986).
95. Latov, N. et al. Monoclonal IgM with unique specificity to gangliosides GM1 and GD1b and to lacto-N-tetraose associated with human motor neuron disease. Neurology 38, 763-768 (1988).
96. Nardelli, E., Steck, A. J., Barkas, T., Schluep, M. & Jerusalem, F. Motor neuron syndrome and monoclonal IgM with antibody activity against gangliosides GM1 and GD1b. Ann. Neurol. 23, 524-528 (1988).
97. Dabby, R., Weimer, L. H., Hays, A. P., Olarte, M. & Latov, N. Antisulfatide antibodies in neuropathy: clinical and electrophysiologic correlates. Neurology 54, 1448-1452 (2000).
98. Takatsu, M. et al. Immunofluorescence study of patients with neuropathy and IgM M proteins. Ann. Neurol. 18, 173-181 (1985).
99. Hays, A. P., Lee, S. S. & Latov, N. Immune reactive C3d on the surface of myelin sheaths in neuropathy. J. Neuroimmunol. 18, 231-244 (1988).
100. Mendell, J. R. et al. Polyneuropathy and IgM monoclonal gammopathy: studies on the pathogenetic role of anti-myelin-associated glycoprotein antibody. Ann. Neurol. 17, 243-254 (1985).
101. Jacobs, J. M. & Scadding, J. W. Morphological changes in IgM paraproteinaemic neuropathy. Acta Neuropathol. 80, 77-84 (1990).
102. Gabriel, J. M. et al. Confocal microscopic localization of anti-myelin-associated glycoprotein autoantibodies in a patient with peripheral neuropathy initially lacking a detectable IgM gammopathy. Acta Neuropathol. 95, 540-546 (1998).
103. Vital, C. et al. Myelin modifications in 8 cases of peripheral neuropathy with Waldenström's macroglobulinemia and anti-MAG activity. Ultrastruct. Pathol. 21, 509-516 (1997).
104. Jonsson, V. et al. Immunoglobulin deposits in peripheral nerve endings detected by skin biopsy in patients with IgM M proteins and neuropathy. Neurology 37, 303-306 (1987).
105. Lombardi, R. et al. IgM deposits on skin nerves in anti-myelin-associated glycoprotein neuropathy. Ann. Neurol. 57, 180-187 (2005).
106. Hays, A. P., Latov, N., Takatsu, M. & Sherman, W. H. Experimental demyelination of nerve induced by serum of patients with neuropathy and an anti-MAG IgM M-protein. Neurology 37, 242-256 (1987).
107. Tatum, A. H. Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti-myelin-associated glycoprotein. Ann. Neurol. 33, 502-506 (1993).
108. Willison, H. J. et al. Demyelination induced by intraneural injection of human antimyelin-associated glycoprotein antibodies. Muscle Nerve 11, 1169-1176 (1988).
109. Trojaborg, W. et al. Electrophysiologic study of experimental demyelination induced by serum of patients with IgM M proteins and neuropathy. Neurology 39, 1581-1586 (1989).
110. Rowland, L. P. et al. Macroglobulinemia with peripheral neuropathy simulating motor neuron disease. Ann. Neurol. 11, 532-536 (1982).
111. Roth, G., Rohr, J., Magistris, M. R. & Ochsner, F. Motor neuropathy with proximal multifocal persistent conduction block, fasciculations and myokymia. Evolution to tetraplegia. Eur. Neurol. 25, 416-423 (1986).
112. Chad, D. A., Hammer, K. & Sargent, J. Slow resolution of multifocal weakness and fasciculation: a reversible motor neuron syndrome. Neurology 36, 1260-1263 (1986).
113. Parry, G. J. & Clarke, S. Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve 11, 103-107 (1988).
114. Pestronk, A. et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann. Neurol. 24, 73-78 (1988).
115. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. J. Peripher. Nerv. Syst. 15, 295-301 (2010).
116. Lambrecq, V., Krim, E., Rouanet-Larriviere, M. & Lagueny, A. Sensory loss in multifocal motor neuropathy: a clinical and electrophysiological study. Muscle Nerve 39, 131-136 (2009).
117. Kaji, R., Shibasaki, H. & Kimura, J. Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy. Neurology 42, 506-509 (1992).
118. Pringle, C. E., Belden, J., Veitch, J. E. & Brown, W. F. Multifocal motor neuropathy presenting as ophthalmoplegia. Muscle Nerve 20, 347-351 (1997).
119. Delmont, E. et al. Multifocal motor neuropathy with and without conduction block: a single entity? Neurology 67, 592-596 (2006).
120. Fischer, D., Grothe, C., Schmidt, S. & Schroder, R. On the early diagnosis of IVIg-responsive chronic multifocal acquired motor axonopathy. J. Neurol. 251, 1204-1207 (2004).
121. Katz, J. S. et al. Axonal multifocal motor neuropathy without conduction block or other features of demyelination. Neurology 58, 615-620 (2002).
122. Pakiam, A. S. & Parry, G. J. Multifocal motor neuropathy without overt conduction block. Muscle Nerve 21, 243-245 (1998).
123. Riva, N. et al. Chronic motor axonal neuropathy. J. Peripher. Nerv. Syst. 16, 341-346 (2011).
124. Vucic, S., Black, K., Chong, P. S. & Cros, D. Multifocal motor neuropathy with conduction block: distribution of demyelination and axonal degeneration. Clin. Neurophysiol. 118, 124-130 (2007).
125. O'Ferrall, E. K., White, C. M. & Zochodne, D. W. Demyelinating symmetric motor polyneuropathy with high titers of anti-GM1 antibodies. Muscle Nerve 42, 604-608 (2010).
126. Kinsella, L. J. et al. Clinical and electrophysiologic correlates of elevated anti-GM1 antibody titers. Neurology 44, 1278-1282 (1994).
127. Van Asseldonk, J. T. et al. Demyelination and axonal loss in multifocal motor neuropathy: distribution and relation to weakness. Brain 126, 186-198 (2003).
128. Auer, R. N., Bell, R. B. & Lee, M. A. Neuropathy with onion bulb formations and pure motor manifestations. Can. J. Neurol. Sci. 16, 194-197 (1989).
129. Gorson, K. C., Ropper, A. H. & Weinberg, D. H. Upper limb predominant, multifocal chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 22, 758-765 (1999).
130. Beydoun, S. R. Multifocal motor neuropathy with conduction block misdiagnosed as multiple entrapment neuropathies. Muscle Nerve 21, 813-815 (1998).
131. Van Es, H. W. et al. Magnetic resonance imaging of the brachial plexus in patients with multifocal motor neuropathy. Neurology 48, 1218-1224 (1997).
132. Beekman, R. et al. Ultrasonography shows extensive nerve enlargements in multifocal motor neuropathy. Neurology 65, 305-307 (2005).
133. Corbo, M. et al. Motor nerve biopsy studies in motor neuropathy and motor neuron disease. Muscle Nerve 20, 15-21 (1997).
134. Dy, C. J. et al. Diagnostic biopsy of the pronator teres and a motor branch of the median nerve: indications and technique. J. Hand Surg. Am. 37, 2570-2575 (2012).
135. Abouzahr, M. K. et al. Diagnostic biopsy of the motor nerve to the gracilis muscle. Technical note. J. Neurosurg. 87, 122-124 (1997).
136. Taylor, B. V., Gross, L. & Windebank, A. J. The sensitivity and specificity of anti-GM1 antibody testing. Neurology 47, 951-955 (1996).
137. Cats, E. A. et al. Multifocal motor neuropathy: association of anti-GM1 IgM antibodies with clinical features. Neurology 75, 1961-1967 (2010).
138. Adams, D. et al. Motor conduction block and high titres of anti-GM1 ganglioside antibodies: pathological evidence of a motor neuropathy in a patient with lower motor neuron syndrome. J. Neurol. Neurosurg. Psychiatry 56, 982-987 (1993).
139. Oh, S. J., Claussen, G. C., Odabasi, Z. & Palmer, C. P. Multifocal demyelinating motor neuropathy: pathologic evidence of 'inflammatory demyelinating polyradiculoneuropathy'. Neurology 45, 1828-1832 (1995).
140. Parry, G. J., Holtz, S. J., Ben-Zeev, D. & Drori, J. B. Gammopathy with proximal motor axonopathy simulating motor neuron disease. Neurology 36, 273-276 (1986).
141. Gorson, K. C., Ropper, A. H., Adelman, L. S., Raynor, E. M. & Saper, C. B. Chronic motor axonal neuropathy: pathological evidence of inflammatory polyradiculoneuropathy. Muscle Nerve 22, 266-270 (1999).
142. Kaji, R. et al. Pathological findings at the site of conduction block in multifocal motor neuropathy. Ann. Neurol. 33, 152-158 (1993).
143. Taylor, B. V., Dyck, P. J., Engelstad, J., Gruener, G. & Grant, I. Multifocal motor neuropathy: pathologic alterations at the site of conduction block. J. Neuropathol. Exp. Neurol. 63, 129-137 (2004).
144. Riva, N. et al. Motor nerve biopsy: clinical usefulness and histopathological criteria. Ann. Neurol. 69, 197-201 (2011).
145. Corse, A. M. et al. Sensory nerve pathology in multifocal motor neuropathy. Ann. Neurol. 39, 319-325 (1996).
146. Nakanishi, T. et al. The Crow-Fukase syndrome: a study of 102 cases in Japan. Neurology 34, 712-720 (1984).
147. Mauermann, M. L. et al. Uniform demyelination and more severe axonal loss distinguish POEMS syndrome from CIDP. J. Neurol. Neurosurg. Psychiatry 83, 480-486 (2012).
148. Albertí, M. A. et al. 18F-FDG PET/CT in the evaluation of POEMS syndrome. Eur. J. Radiol. 76, 180-182 (2010).
149. Briani, C. et al. Vascular endothelial growth factor helps differentiate neuropathies in rare plasma cell dyscrasias. Muscle Nerve 43, 164-167 (2011).
150. Nobile-Orazio, E., Terenghi, F., Giannotta, C., Gallia, F. & Nozza, A. Serum VEGF levels in POEMS syndrome and in immune-mediated neuropathies. Neurology 72, 1024-1026 (2009).
151. Umehara, F., Izumo, S., Zyounosono, M. & Osame, M. An autopsied case of the Crow-Fukase syndrome: a neuropathological study with emphasis on spinal roots. Acta Neuropathol. 80, 563-567 (1990).
152. Sobue, G., Doyu, M., Watanabe, M., Hayashi, F. & Mitsuma, T. Extensive demyelinating changes in the peripheral nerves of Crow-Fukase syndrome: a pathological study of one autopsied case. Acta Neuropathol. 84, 171-177 (1992).
153. Vital, C. et al. Crow-Fukase (POEMS) syndrome: a study of peripheral nerve biopsy in five new cases. J. Peripher. Nerv. Syst. 8, 136-144 (2003).
154. Kanda, T. Pathology of Crow-Fukase syndrome [Japanese]. Brain Nerve 60, 603-610 (2008).
155. Hughes, R. A. et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 7, 136-144 (2008).
156. Dyck, P. J. et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 36, 838-845 (1994).
157. Hahn, A. F. et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 119, 1055-1066 (1996).
158. van Schaik, I. N. et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol. 9, 245-253 (2010).
159. Hahn, A. F., Bolton, C. F., Zochodne, D. & Feasby, T. E. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 119, 1067-1077 (1996).
160. Nobile-Orazio, E. et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol. 11, 493-502 (2012).
161. Eftimov, F., Liesdek, M. H., Verhamme, C. & van Schaik, I. N. Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern. BMC Neurol. 14, 72 (2014).
162. Cocito, D. et al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur. J. Neurol. 17, 289-294 (2010).
163. Gorson, K. C., Allam, G. & Ropper, A. H. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 48, 321-328 (1997).
164. Mahdi-Rogers, M., van Doorn, P. A. & Hughes, R. A. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD003280. http://dx.doi.org/10.1002/ 14651858.CD003280.pub4.
165. Latov, N. et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch. Neurol. 67, 802-807 (2010).
166. Barohn, R. J., Kissel, J. T., Warmolts, J. R. & Mendell, J. R. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch. Neurol. 46, 878-884 (1989).
167. Vanhoutte, E. K., Faber, C. G. & Merkies, I. S. 196th ENMC international workshop: outcome measures in inflammatory peripheral neuropathies 8-10 February 2013, Naarden, The Netherlands. Neuromuscul. Disord. 23, 924-933 (2013).
168. Iijima, M. et al. Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP. Neurology 64, 1471-1475 (2005).
169. Querol, L. et al. Long-term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: a retrospective study. Muscle Nerve 48, 870-876 (2013).
170. Lunn, M. P., Manji, H., Choudhary, P. P., Hughes, R. A. & Thomas, P. K. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J. Neurol. Neurosurg. Psychiatry 66, 677-680 (1999).
171. Rabin, M. et al. Chronic inflammatory demyelinating polyradiculoneuropathy: search for factors associated with treatment dependence or successful withdrawal. J. Neurol. Neurosurg. Psychiatry http://dx.doi.org/10. 1136/jnnp-2013-306105.
172. Vucic, S. et al. Long-term effects of intravenous immunoglobulin in CIDP. Clin. Neurophysiol. 118, 1980-1984 (2007).
173. Seguro, L. P., Rosario, C. & Shoenfeld, Y. Long-term complications of past glucocorticoid use. Autoimmun. Rev. 12, 629-632 (2013).
174. Dalakas, M. C. Pathogenesis and treatment of anti-MAG neuropathy. Curr. Treat. Options Neurol. 12, 71-83 (2010).
175. Lunn, M. P. & Nobile-Orazio, E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database of Systematic Reviews 2012, Issue 5. Art. No.: CD002827. http://dx.doi.org/10.1002/14651858.CD002827.pub3.
176. Koya, J. et al. Fludarabine may overcome resistance to rituximab in IgM-related neuropathy. J. Neurol. Sci. 315, 150-152 (2012).
177. Gruson, B. et al. Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy. J. Peripher. Nerv. Syst. 16, 180-185 (2011).
178. Hospital, M. A. et al. Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patients. Haematologica 98, e155-e157 (2013).
179. Dalakas, M. C. et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann. Neurol. 65, 286-293 (2009).
180. Leger, J. M. et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology 80, 2217-2225 (2013).
181. Nobile-Orazio, E., Vietorisz, T., Messito, M. J., Sherman, W. H. & Latov, N. Anti-MAG IgM antibodies in patients with neuropathy and IgM M proteins: detection by ELISA. Neurology 33, 939-942 (1983).
182. Kelly, J. J., Adelman, L. S., Berkman, E. & Bhan, I. Polyneuropathies associated with IgM monoclonal gammopathies. Arch. Neurol. 45, 1355-1359 (1988).
183. Stork, A. C., Notermans, N. C., Vrancken, A. F., Cornblath, D. R. & van der Pol, W. L. Rapid worsening of IgM anti-MAG demyelinating polyneuropathy during rituximab treatment. J. Peripher. Nerv. Syst. 18, 189-191 (2013).
184. Motoyama, R., Yamakawa, K., Suzuki, S., Kusunoki, S. & Tanaka, M. Rapid improvement by rituximab treatment in a case of demyelinating polyneuropathy with anti-myelin-associated glycoprotein antibody [Japanese].
185. Hahn, A. F. et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. J. Peripher. Nerv. Syst. 18, 321-330 (2013).
186. van Schaik, I. N., van den Berg, L. H., de Haan, R. & Vermeulen, M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD004429. http://dx.doi.org/10. 1002/14651858.CD004429.pub2.
187. Feldman, E. L., Bromberg, M. B., Albers, J. W. & Pestronk, A. Immunosuppressive treatment in multifocal motor neuropathy. Ann. Neurol. 30, 397-401 (1991).
188. Donaghy, M. et al. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J. Neurol. Neurosurg. Psychiatry 57, 778-783 (1994).
189. Carpo, M. et al. Deterioration of multifocal motor neuropathy after plasma exchange. Neurology 50, 1480-1482 (1998).
190. Vucic, S., Black, K. R., Chong, P. S. & Cros, D. Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg. Neurology 63, 1264-1269 (2004).
191. Baumann, A., Hess, C. W. & Sturzenegger, M. IVIg dose increase in multifocal motor neuropathy: a prospective six month follow-up. J. Neurol. 256, 608-614 (2009).
192. Gronier, S. et al. Efficacy of autologous peripheral blood stem cell transplantation (auto-PBSCT) on the neuropathic manifestations in POEMS syndrome [French]. Rev. Neurol. (Paris) 170, 37-45 (2014).
193. Zagouri, F. et al. Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. Leuk. Lymphoma http://dx.doi.org/10.3109/ 10428194.2013.869329.
194. Cho, Y. et al. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc. Natl Acad. Sci. USA 107, 11313-11318 (2010).
195. Robak, T. & Robak, E. Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders. Expert Opin. Investig. Drugs 21, 921-947 (2012).